26-08-2022 14:05:06 | Current | ESPI | 12/2022
Article 17 (1) MAR – confidential information.
Contents of the report:
The Management Board of Median Polska S.A. with its seat in Mysłowice _hereinafter: the Company_, in reference to the ESPI report no. 12/2021 dated December 13, 2021. _in which it reported on its decision to start talks related to the development of its business_ and ESPI Report No. 4/2022 dated April 13, 2022. _in which it reported on the commencement of negotiations on the acquisition of assets and competencies to conduct business in the area of nutraceuticals and dietary supplements production_ informs that, as a consequence of the completion of negotiations, today it has decided to acquire assets in the form of 100% of shares in Hempley sp. z o.o., based in Gdansk.
In connection with the above, the Company’s Management Board plans to convene a general meeting in the near future, the agenda of which will include, in particular, the adoption of resolutions on:
1_ changing the Company’s name and registered office,
2_ expansion of the Company’s business focus to include activities in the area of dietary supplements production,
3_ increasing the Company’s share capital through a new issue of shares, excluding the pre-emptive rights of existing shareholders, and amending the Company’s Articles of Association, which shares will be offered, to the shareholders of Hempley sp. z o.o. with its seat in Gdansk,
4_ changes in the Company’s governing bodies.
Detailed information on the wording of the Company’s new company name, the subject matter of its operations, as well as the parity of exchange of Hempley sp. z o.o. shares for the Company’s shares _still being determined at present_, will be provided no later than the date of the convening of the general meeting.
The Board of Directors indicates that the final decision regarding the acquisition of Hempley sp. z o.o. shares and the commencement of operations in the new area will be made by the Shareholders at the general meeting.
In addition, the Management Board indicates that it plans to create a capital group, within which operations will be concentrated in the area of production of nutraceuticals and dietary supplements.
- Martyna Serafin – President of the Management Board